LipoScience Stock Soars On Vantera® Clinical Analyzer Prospects (NASDAQ:LPDX)

LipoScience, Inc. (NASDAQ:LPDX)

While America remains bullish towards stocks, check out LipoScience, Inc. ticker symbol LPDX. LipoScience is a Company that specializes in diagnostics based on nuclear magnetic resonance technology targeting conditions of heart disease. In the financial markets, LipoScience has surged +14.59% Up 0.55 generating over 227K shares in play Wednesday November 27, 2013 3:21PM EST. What’s pushing LipoScience (www.liposcience.com) stock Up you ask? The Answer would be the Vantera® Clinical Analyzer.

The Vantera® Clinical Analyzer is the first nuclear magnetic resonance cleared by the U S Food and Drug Administration, that processes algorithms to identify and quantify concentrations of lipoproteins. Lipoproteins is a biochemical assembly that contains both proteins and lipids, bound to the proteins, which allow fats to move through the water inside and outside cells. As we all should know that a majority of heart attacks are due from a complications involving clogged arteries. With the global market of cardiovascular treatments generating over $109 billion last year 2012, It would be safe to assume that Vantera® Clinical Analyzer within Scripps Health facilities is huge. With the Affordable Care Act taking stage next year nuclear magnetic resonance technology has expanded its potential to become a clinical standard of care.

****

Durata Therapeutics, Inc. (NASDAQ:DRTX)

While we’re on the topic of health care, take a look at Durata Therapeutics ticker symbol DRTX. Durata Therapeutics specializes as a bio pharmaceutical company targeting infectious diseases and illnesses with therapuetic treatments. In the financial markets, Durata Therapeutics has surged +7.87% Up 0.85 generating over 522K shares in play Wednesday November 27, 2013 3:50PM EST. What’s makes Durata Therapeutics (www.duratatherapeutics.com) stock hot you ask? The Answer is Dalvance(TM) (dalbavancin hydrochlorid).

The U S Food and Drug Administration accepted a New Drug Application concerning Dalvance(TM).  Turns out that Dalvance(TM)  has been accepted for the purpose of  treating acute bacterial skin and skin structure infections. The global skin structure infection therapeutics market is estimated to reach over $1.57 billion this year 2013. Once again, with the Affordable Care Act taking stage next year Dalvance(TM) technology has potential to become a clinical standard of care in hospital and ambulatory situations.

Read Full Disclaimer at http://crwefinance.com/disclaimer/

Remember: Always do your homework and consult your own financial professional.